ICI 2013---15th International Congress of Immunology
Poster Presentation (P6.11.78)
Frontiers Immunology (Electronic ISSN:1664-3224), doi: 10.3389/conf.fimmu.2013.02.00895.
Bang-FU Wu1, 2* and Jiang-Ying Yang2
-
1 Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, China
-
2 Guangzhou Pubang Bio-Immunological Tech Research Institute, China
Aims: To observe the clinical efficacy of the admixture of hepatitis B vaccine, rhGM-CSF and BCG polysaccharide ucleic acid(for short: hepatitis B vaccine triple-therapy) combined with adefovir dipivoxil in the patients of chronic hepatitis B virus(HBV) infection.
Methods: 18 HBeAg positive chronic hepatitis B(CHB) patients, 11 HBeAg positive chronic HBV carriers, 5 HBeAg negative CHB patients, 2 HBeAg negative chronic HBV carriers and 12 inactive HBsAg carriers were recruited in the study. Hepatitis B vaccine containing 20µg HBsAg, rhGM-CSF 100µg and BCG polysaccharide nucleic acid 2ml were mixed. And then the admixture injected hypodermically to the patient once every two weeks for 12 practices applications totally. Adefovir dipivoxil was taken 10mg daily for 33 patients those HBVDNA>10000 copy/ml. Quantitative HBVM(TRFIA) and HBVDNA were evaluated at week 0, 12, and 24.
Results: At week 12 and 24, HBeAg seroconversion rate were 13.79%(4/29) and 27.59%(8/29) respectively, HBVDNA negative conversion rate were 37.14%(13/35), and 60.00%(21/35), HBsAg negative conversion rate were 2.08%(1/48) and 6.25%(3/48), HBsAb positive conversion rate were 16.67%(8/48) and 37.50%(18/48), HBsAg seroconversion rate were 2.08%(1/48) and 6.25%(3/48).
The rate of adverse effect was 50.17%. The adverse effect include fever, headache, ache all over, bellyache, urticaria and hives, dyspnea, and tumefaction ache in the injection site after injected the admixture.
Conclusions: The hepatitis B vaccine triple-therapy in combination with adefovir dipivoxil can be considered as a efficient approach for patients of chronic HBV infection, which may effectively inhibit the viral replication, improve the production of HBsAb and HBeAb, and increase HBeAg seroconversion rate.
Keywords: Hepatitis B virus (HBV), Chronic hepatitis B (CHB), Hepatitis B vaccine, Chronic HBV carriers, rhGM-CSF
Conference: 15th International Congress of Immunology (ICI), Milan, Italy, 22 Aug - 27 Aug, 2013.
Presentation Type: Abstract
Topic: Translational immunology and immune intervention
Citation: Wu B and Yang J (2013). A clinical study on hepatitisi B vaccine triple-therapy in chronic hepatitis B virus infection. Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00895
Received: 20 Jun 2013; Published Online: 22 Aug 2013.
* Correspondence: Prof. Bang-FU Wu, Southern Medical University Renkang Hospital, Gastroenterology and Hepatology Center, Dongguan, Guangdong, 523952, China, bangfu.wu@163.com
|
